These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 37889103)

  • 1. Canonical and Nuclear mTOR Specify Distinct Transcriptional Programs in Androgen-Dependent Prostate Cancer Cells.
    Chen Y; Han L; Dufour CR; Alfonso A; Giguère V
    Mol Cancer Res; 2024 Feb; 22(2):113-124. PubMed ID: 37889103
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nuclear mTOR acts as a transcriptional integrator of the androgen signaling pathway in prostate cancer.
    Audet-Walsh É; Dufour CR; Yee T; Zouanat FZ; Yan M; Kalloghlian G; Vernier M; Caron M; Bourque G; Scarlata E; Hamel L; Brimo F; Aprikian AG; Lapointe J; Chevalier S; Giguère V
    Genes Dev; 2017 Jun; 31(12):1228-1242. PubMed ID: 28724614
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The mTOR chromatin-bound interactome in prostate cancer.
    Dufour CR; Scholtes C; Yan M; Chen Y; Han L; Li T; Xia H; Deng Q; Vernier M; Giguère V
    Cell Rep; 2022 Mar; 38(12):110534. PubMed ID: 35320709
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SREBF1 Activity Is Regulated by an AR/mTOR Nuclear Axis in Prostate Cancer.
    Audet-Walsh É; Vernier M; Yee T; Laflamme C; Li S; Chen Y; Giguère V
    Mol Cancer Res; 2018 Sep; 16(9):1396-1405. PubMed ID: 29784665
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Crosstalk between androgen and pro-inflammatory signaling remodels androgen receptor and NF-κB cistrome to reprogram the prostate cancer cell transcriptome.
    Malinen M; Niskanen EA; Kaikkonen MU; Palvimo JJ
    Nucleic Acids Res; 2017 Jan; 45(2):619-630. PubMed ID: 27672034
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cooperativity and equilibrium with FOXA1 define the androgen receptor transcriptional program.
    Jin HJ; Zhao JC; Wu L; Kim J; Yu J
    Nat Commun; 2014 May; 5():3972. PubMed ID: 24875621
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integration of regulatory networks by NKX3-1 promotes androgen-dependent prostate cancer survival.
    Tan PY; Chang CW; Chng KR; Wansa KD; Sung WK; Cheung E
    Mol Cell Biol; 2012 Jan; 32(2):399-414. PubMed ID: 22083957
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DNA-PK, Nuclear mTOR, and the Androgen Pathway in Prostate Cancer.
    Giguère V
    Trends Cancer; 2020 Apr; 6(4):337-347. PubMed ID: 32209447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. mTOR is a fine tuning molecule in CDK inhibitors-induced distinct cell death mechanisms via PI3K/AKT/mTOR signaling axis in prostate cancer cells.
    Berrak O; Arisan ED; Obakan-Yerlikaya P; Coker-Gürkan A; Palavan-Unsal N
    Apoptosis; 2016 Oct; 21(10):1158-78. PubMed ID: 27484210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Darolutamide antagonizes androgen signaling by blocking enhancer and super-enhancer activation.
    Baumgart SJ; Nevedomskaya E; Lesche R; Newman R; Mumberg D; Haendler B
    Mol Oncol; 2020 Sep; 14(9):2022-2039. PubMed ID: 32333502
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulation of androgen receptor transcriptional activity by rapamycin in prostate cancer cell proliferation and survival.
    Wang Y; Mikhailova M; Bose S; Pan CX; deVere White RW; Ghosh PM
    Oncogene; 2008 Nov; 27(56):7106-17. PubMed ID: 18776922
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PI3K-AKT-mTOR pathway is dominant over androgen receptor signaling in prostate cancer cells.
    Kaarbø M; Mikkelsen OL; Malerød L; Qu S; Lobert VH; Akgul G; Halvorsen T; Maelandsmo GM; Saatcioglu F
    Cell Oncol; 2010; 32(1-2):11-27. PubMed ID: 20203370
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual role of FoxA1 in androgen receptor binding to chromatin, androgen signalling and prostate cancer.
    Sahu B; Laakso M; Ovaska K; Mirtti T; Lundin J; Rannikko A; Sankila A; Turunen JP; Lundin M; Konsti J; Vesterinen T; Nordling S; Kallioniemi O; Hautaniemi S; Jänne OA
    EMBO J; 2011 Sep; 30(19):3962-76. PubMed ID: 21915096
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dissecting transcription of the 8q24-MYC locus in prostate cancer recognizes the equilibration between androgen receptor direct and indirect dual-functions.
    Guo J; Wei Z; Jia T; Wang L; Nama N; Liang J; Liao X; Liu X; Gao Y; Liu X; Wang K; Fu B; Chen SS
    J Transl Med; 2023 Oct; 21(1):716. PubMed ID: 37828515
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Androgen Receptor Enhances p27 Degradation in Prostate Cancer Cells through Rapid and Selective TORC2 Activation.
    Fang Z; Zhang T; Dizeyi N; Chen S; Wang H; Swanson KD; Cai C; Balk SP; Yuan X
    J Biol Chem; 2012 Jan; 287(3):2090-8. PubMed ID: 22139837
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resveratrol regulates the PTEN/AKT pathway through androgen receptor-dependent and -independent mechanisms in prostate cancer cell lines.
    Wang Y; Romigh T; He X; Orloff MS; Silverman RH; Heston WD; Eng C
    Hum Mol Genet; 2010 Nov; 19(22):4319-29. PubMed ID: 20729295
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Skp2 regulates androgen receptor through ubiquitin-mediated degradation independent of Akt/mTOR pathways in prostate cancer.
    Li B; Lu W; Yang Q; Yu X; Matusik RJ; Chen Z
    Prostate; 2014 Apr; 74(4):421-32. PubMed ID: 24347472
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Androgen receptor and chemokine receptors 4 and 7 form a signaling axis to regulate CXCL12-dependent cellular motility.
    Hsiao JJ; Ng BH; Smits MM; Wang J; Jasavala RJ; Martinez HD; Lee J; Alston JJ; Misonou H; Trimmer JS; Wright ME
    BMC Cancer; 2015 Mar; 15():204. PubMed ID: 25884570
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual targeting of the androgen receptor and PI3K/AKT/mTOR pathways in prostate cancer models improves antitumor efficacy and promotes cell apoptosis.
    Sugawara T; Nevedomskaya E; Heller S; Böhme A; Lesche R; von Ahsen O; Grünewald S; Nguyen HM; Corey E; Baumgart SJ; Georgi V; Pütter V; Fernández-Montalván A; Vasta JD; Robers MB; Politz O; Mumberg D; Haendler B
    Mol Oncol; 2024 Mar; 18(3):726-742. PubMed ID: 38225213
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Src promotes castration-recurrent prostate cancer through androgen receptor-dependent canonical and non-canonical transcriptional signatures.
    Chattopadhyay I; Wang J; Qin M; Gao L; Holtz R; Vessella RL; Leach RW; Gelman IH
    Oncotarget; 2017 Feb; 8(6):10324-10347. PubMed ID: 28055971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.